Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort.

Aftercare Breast neoplasms Cancer survivors Guideline adherence Long-term survivors Mammography

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 24 01 2022
accepted: 02 03 2022
pubmed: 16 3 2022
medline: 14 5 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

To identify adherence to follow-up recommendations in long-term breast cancer survivors (LTBCS) of the SURBCAN cohort and to identify its determinants, using real-world data. We conducted a retrospective study using electronic health records from 2012 to 2016 of women diagnosed with incident breast cancer in Spain between 2000 and 2006 and surviving at least 5 years. Adherence to basic follow-up recommendations, adherence according to risk of recurrence, and overall adherence were calculated based on attendance at medical appointments and imaging surveillance, by year of survivorship. Logistic regression models were fitted to depict the association between adherence and its determinants. A total of 2079 LTBCS were followed up for a median of 4.97 years. Of them, 23.6% had survived ≥ 10 years at baseline. We estimated that 79.5% of LTBCS were overall adherent to at least one visit and one imaging test. Adherence to recommendations decreased over time and no differences were found according to recurrence risk. Determinants of better overall adherence were diagnosis in middle age (50-69 years old), living in a more-deprived area, having fewer years of survival, receiving primary treatment, and being alive at the end of follow-up. We identified women apparently not complying with surveillance visits and tests. Special attention should be paid to the youngest and eldest women at diagnosis and to those with longer survival.

Identifiants

pubmed: 35290544
doi: 10.1007/s10549-022-06563-x
pii: 10.1007/s10549-022-06563-x
pmc: PMC9090857
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

455-465

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI16/0024
Organisme : Instituto de Salud Carlos III
ID : PI19/00056
Organisme : Research Network on Health Services in Chronic Diseases
ID : RD16/001/013

Informations de copyright

© 2022. The Author(s).

Références

Breast Cancer Res Treat. 2009 Apr;114(3):403-12
pubmed: 18421576
J Clin Oncol. 2016 Feb 20;34(6):611-35
pubmed: 26644543
Int J Surg. 2005;3(3):179-87
pubmed: 17462282
Br J Cancer. 2010 Mar 30;102(7):1085-90
pubmed: 20234361
J Clin Oncol. 2011 Dec 20;29(36):4755-62
pubmed: 22042959
Cancer Control. 2020 Jan-Dec;27(1):1073274820917208
pubmed: 32233798
J Gen Intern Med. 2009 Apr;24(4):469-74
pubmed: 19156470
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Int J Epidemiol. 2006 Apr;35(2):345-52
pubmed: 16368724
J Natl Compr Canc Netw. 2018 May;16(5):526-534
pubmed: 29752327
J Clin Oncol. 2017 Sep 20;35(27):3123-3130
pubmed: 28749724
Gac Sanit. 2008 May-Jun;22(3):179-87
pubmed: 18579042
J Natl Cancer Inst. 2020 Jan 1;112(1):111-113
pubmed: 31613369
Breast. 2017 Dec;36:89-95
pubmed: 28988610
Fam Pract. 2013 Oct;30(5):525-32
pubmed: 23813864
J Clin Oncol. 2006 Feb 20;24(6):848-55
pubmed: 16418496
J Cancer Surviv. 2019 Jun;13(3):477-493
pubmed: 30968367
Breast Cancer Res. 2008;10(5):R83
pubmed: 18844974
Can Fam Physician. 2016 Oct;62(10):805-811
pubmed: 27737976
Int J Breast Cancer. 2012;2012:347646
pubmed: 23097709
Am J Public Health. 1998 Nov;88(11):1713-5
pubmed: 9807544
BMC Health Serv Res. 2017 Nov 13;17(1):716
pubmed: 29132423
Int J Cancer. 2013 May 15;132(10):2404-12
pubmed: 23047687
BMJ Open. 2020 Sep 9;10(9):e040253
pubmed: 32912957
Breast Cancer Res Treat. 2016 Aug;158(3):543-51
pubmed: 27393619
Breast Cancer Res Treat. 2003 Sep;81(2):107-15
pubmed: 14572153
J Clin Oncol. 2006 Jan 1;24(1):85-94
pubmed: 16382117
Eur J Oncol Nurs. 2012 Jul;16(3):281-5
pubmed: 21816672
BMC Cancer. 2011 Jun 28;11:279
pubmed: 21708039
Breast Cancer Res Treat. 2014 Feb;143(3):541-50
pubmed: 24407530
Int J Environ Res Public Health. 2019 Aug 22;16(17):
pubmed: 31443512
Cancer. 2006 Jun 1;106(11):2482-8
pubmed: 16634097
Med Care. 2000 Mar;38(3):281-9
pubmed: 10718353
Gac Sanit. 2005 Jan-Feb;19(1):15-21
pubmed: 15745664
Cancer Invest. 2007 Dec;25(8):758-65
pubmed: 17952742
J Gen Intern Med. 2008 Feb;23(2):158-63
pubmed: 18060463
J Clin Oncol. 2006 Nov 10;24(32):5117-24
pubmed: 17093273

Auteurs

Paula Santiá (P)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Preventive Medicine and Public Health Teaching Unit (Hospital del Mar - Barcelona Public Health Agency - Pompeu Fabra University), Barcelona, Spain.

Anna Jansana (A)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
European Higher Education Area Doctoral Program in Methodology of Biomedical Research and Public Health in Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Autonomous University of Barcelona (UAB), Bellaterra, Barcelona, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.

Isabel Del Cura (I)

Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.
Primary Care Research Unit, Madrid Health Service, Calle San Martín de Porres, 6-5ª planta, 28035, Madrid, Spain.
Department of Preventive Medicine and Public Health, Rey Juan Carlos University, Avenida de Atenas, 28922, Alcorcón, Madrid, Spain.

Maria Padilla-Ruiz (M)

Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.
Research Unit, Costa del Sol Hospital, Biomedical Research Institute of Málaga (IBIMA), University of Málaga, Marbella, Spain.

Laia Domingo (L)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.

Javier Louro (J)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.

Mercè Comas (M)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.

Teresa Sanz (T)

Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.
Primary Care Research Unit, Madrid Health Service, Calle San Martín de Porres, 6-5ª planta, 28035, Madrid, Spain.

Talita Duarte-Salles (T)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.

Maximino Redondo (M)

Research Unit, Costa del Sol Hospital, Biomedical Research Institute of Málaga (IBIMA), University of Málaga, Marbella, Spain.

Berta Ibañez (B)

Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.
Navarrabiomed, Hospital Complex of Navarra, Public University of Navarra, IdiSNA, Irunlarrea, s/n, 31008, Pamplona, Spain.

Alexandra Prados-Torres (A)

Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.
EpiChron Research Group On Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital Pl +2, Paseo Isabel la Católica 1-3, 50009, Saragossa, Spain.

Xavier Castells (X)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain.
Autonomous University of Barcelona (UAB), 08193, Bellaterra, Barcelona, Spain.
Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Institute of Health Carlos III, Madrid, Spain.

Maria Sala (M)

Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute (IMIM), Passeig Marítim, 25-29, 08003, Barcelona, Spain. msalaserra@parcdesalutmar.cat.
Health Services Research on Chronic Patients Network (REDISSEC), Institute of Health Carlos III, Madrid, Spain. msalaserra@parcdesalutmar.cat.
Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Institute of Health Carlos III, Madrid, Spain. msalaserra@parcdesalutmar.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH